Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Loganzo, Frank, Tan, Xingzhi, Sung, Matthew, Jin, Guixian, Myers, Jeremy S., Melamud, Eugene, Wang, Fang, Diesl, Veronica, Follettie, Maximillian T., Musto, Sylvia, Lam, My-Hanh, Hu, William, Charati, Manoj B., Khandke, Kiran, Kim, Kenny Sung Kyoo, Cinque, Mike, Lucas, Judy, Graziani, Edmund, Maderna, Andreas, O'Donnell, Christopher J., Arndt, Kim T., Gerber, Hans-Peter·2015·Molecular Cancer Therapeutics

Abstract

Antibody–drug conjugates (ADC) are emerging as clinically effective therapy. We hypothesized that cancers treated with ADCs would acquire resistance mechanisms unique to immunoconjugate therapy and that changing ADC components may overcome resistance. Breast cancer cell lines were exposed to multiple cycles of anti-Her2 trastuzumab–maytansinoid ADC (TM-ADC) at IC80 concentrations followed by recovery. The resistant cells, 361-TM and JIMT1-TM, were characterized by cytotoxicity, proteomic, transcriptional, and other profiling. Approximately 250-fold resistance to TM-ADC developed in 361-TM cells, and cross-resistance was observed to other non–cleavable-linked ADCs. Strikingly, these 361-TM cells retained sensitivity to ADCs containing cleavable mcValCitPABC-linked auristatins. In JIMT1-TM cells, 16-fold resistance to TM-ADC developed, with cross-resistance to other trastuzumab-ADCs. Both 361-TM and JIMT1-TM cells showed minimal resistance to unconjugated mertansine (DM1) and other chemotherapeutics. Proteomics and immunoblots detected increased ABCC1 (MRP1) drug efflux protein in 361-TM cells, and decreased Her2 (ErbB2) in JIMT1-TM cells. Proteomics also showed alterations in various pathways upon chronic exposure to the drug in both cell models. Tumors derived from 361-TM cells grew in mice and were refractory to TM-ADC compared with parental cells. Hence, acquired resistance to trastuzumab–maytansinoid ADC was generated in cultured cancer cells by chronic drug treatment, and either increased ABCC1 protein or reduced Her2 antigen were primary mediators of resistance. These ADC-resistant cell models retain sensitivity to other ADCs or standard-of-care chemotherapeutics, suggesting that alternate therapies may overcome acquired ADC resistance. Mol Cancer Ther; 14(4); 952–63. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-14-0862

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 278

Metadata

Authors
Loganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., Musto, S., Lam, M.-H., Hu, W., Charati, M. B., Khandke, K., Kim, K. S. K., Cinque, M., Lucas, J., Graziani, E., Maderna, A., O'Donnell, C. J., Arndt, K. T., & Gerber, H.-P.
Venue
Molecular Cancer Therapeutics
Published
2015-04-01
Volume
14
Issue
4
Pages
952-963
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2163851812
Cited by
278
References
44
FWCI
6.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0862
The paper
Loganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., Musto, S., Lam, M.-H., Hu, W., Charati, M. B., Khandke, K., Kim, K. S. K., Cinque, M., Lucas, J., Graziani, E., Maderna, A., . . . Gerber, H.-P. (2015). Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0862

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.